(Q38786561)

6 September 2017

title

Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia (English)

1 reference

6 September 2017

0 references

M Raouf

1

1 reference

6 September 2017

A J Glogowski

series ordinal

2

1 reference

6 September 2017

J J Bettinger

series ordinal

3

1 reference

6 September 2017

J Fudin

series ordinal

4

1 reference

6 September 2017

publication date

15 May 2017

1 reference

Journal of Clinical Pharmacy and Therapeutics

6 September 2017

published in

1 reference

6 September 2017

volume

42

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

513-517

1 reference

Antidepressants in the treatment of neuropathic pain

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Neuronal plasticity: increasing the gain in pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Central modulation of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Noradrenergic pain modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Treatment of pain syndromes with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Venlafaxine in neuropathic pain following treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

The influence of smoking on the serum level of duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Milnacipran inhibits glutamatergic N-methyl-D-aspartate receptor activity in spinal dorsal horn neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Levomilnacipran: a newly approved drug for treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Mechanistic and functional differentiation of tapentadol and tramadol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Postmortem redistribution of tramadol and O-desmethyltramadol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Serotonin syndrome with tramadol and citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

Serotonin syndrome associated with tramadol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12534

21 January 2018

Identifiers

DOI

10.1111/JCPT.12534

1 reference

6 September 2017

1 reference